Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker NKTR
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 186 | $13.4K | — | Aug 18, 2026 | Form 4 ↗ 2 days later · 186 shares | Form 144 ↗ |
| Aug 18, 2026 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 418 | $30.1K | — | Aug 18, 2026 | Form 4 ↗ 2 days later · 418 shares | Form 144 ↗ |
| Jun 30, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 5,681 | $371.5K | 10b5-1 | Jun 30, 2026 | Form 4 ↗ 2 days later · 5,681 shares | Form 144 ↗ |
| Jun 17, 2026 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 10,000 | $602.7K | 10b5-1 | Jun 17, 2026 | Form 4 ↗ 1 day later · 20,000 shares | Form 144 ↗ |
| Jun 16, 2026 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 10,000 | $609.6K | 10b5-1 | Jun 16, 2026 | Form 4 ↗ 2 days later · 20,000 shares | Form 144 ↗ |
| Jun 15, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 5,538 | $328.8K | 10b5-1 | Jun 15, 2026 | Form 4 ↗ 2 days later · 5,538 shares | Form 144 ↗ |
| May 19, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 199 | $13.0K | — | May 19, 2026 | Form 4 ↗ 2 days later · 199 shares | Form 144 ↗ |
| May 19, 2026 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 444 | $29.1K | — | May 19, 2026 | Form 4 ↗ 2 days later · 444 shares | Form 144 ↗ |
| Mar 13, 2026 | Mark Andrew Wilson Former Officer | NKTR Nektar Therapeutics | 78,510 | $5.7M | — | Mar 13, 2026 | — | Form 144 ↗ |
| Feb 18, 2026 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 423 | $30.9K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 423 shares | Form 144 ↗ |
| Feb 18, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 180 | $13.1K | — | Feb 18, 2026 | Form 4 ↗ 2 days later · 180 shares | Form 144 ↗ |
| Jan 20, 2026 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 3,867 | $137.9K | 10b5-1 | Jan 20, 2026 | Form 4 ↗ 2 days later · 3,867 shares | Form 144 ↗ |
| Nov 25, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 2,207 | $129.8K | — | Nov 25, 2025 | Form 4 ↗ same day · 2,207 shares | Form 144 ↗ |
| Nov 25, 2025 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 630 | $37.1K | — | Nov 25, 2025 | Form 4 ↗ same day · 630 shares | Form 144 ↗ |
| Nov 25, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 1,157 | $68.1K | — | Nov 25, 2025 | Form 4 ↗ same day · 1,157 shares | Form 144 ↗ |
| Sep 9, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 6,666 | $311.2K | 10b5-1 | Sep 9, 2025 | Form 4 ↗ 2 days later · 6,666 shares | Form 144 ↗ |
| Sep 5, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 6,666 | $256.8K | 10b5-1 | Sep 5, 2025 | Form 4 ↗ 3 days later · 11,832 shares | Form 144 ↗ |
| Sep 4, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 5,166 | $174.1K | 10b5-1 | Sep 4, 2025 | Form 4 ↗ 4 days later · 11,832 shares | Form 144 ↗ |
| Sep 4, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 1,721 | $57.7K | 10b5-1 | Sep 4, 2025 | Form 4 ↗ 4 days later · 1,721 shares | Form 144 ↗ |
| Sep 2, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 485 | $14.6K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ 2 days later · 485 shares | Form 144 ↗ |
| Sep 2, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 1,500 | $45.2K | 10b5-1 | Sep 2, 2025 | Form 4 ↗ 2 days later · 1,500 shares | Form 144 ↗ |
| Aug 19, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 1,573 | $41.8K | — | Aug 19, 2025 | Form 4 ↗ 2 days later · 1,573 shares | Form 144 ↗ |
| Aug 19, 2025 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 676 | $18.0K | — | Aug 19, 2025 | Form 4 ↗ 2 days later · 676 shares | Form 144 ↗ |
| Aug 19, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 725 | $19.3K | — | Aug 19, 2025 | Form 4 ↗ 2 days later · 725 shares | Form 144 ↗ |
| May 19, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 10,712 | $7,191 | — | May 19, 2025 | Form 4 ↗ 2 days later · 10,712 shares | Form 144 ↗ |
| May 19, 2025 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 9,996 | $6,710 | — | May 19, 2025 | Form 4 ↗ 2 days later · 9,996 shares | Form 144 ↗ |
| May 19, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 23,208 | $15.6K | — | May 19, 2025 | Form 4 ↗ 2 days later · 23,208 shares | Form 144 ↗ |
| Feb 19, 2025 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 11,040 | $11.1K | — | Feb 19, 2025 | Form 4 ↗ 2 days later · 11,040 shares | Form 144 ↗ |
| Feb 19, 2025 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 23,774 | $24.0K | — | Feb 19, 2025 | Form 4 ↗ 2 days later · 23,774 shares | Form 144 ↗ |
| Feb 19, 2025 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 10,300 | $10.4K | — | Feb 19, 2025 | Form 4 ↗ 2 days later · 10,300 shares | Form 144 ↗ |
| Dec 26, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 16,560 | $14.8K | — | Dec 24, 2024 | Form 4 ↗ 57 days later · 11,040 shares | Form 144 ↗ |
| Dec 23, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 33,402 | $29.9K | — | Dec 23, 2024 | Form 4 ↗ 3 days later · 49,962 shares | Form 144 ↗ |
| Dec 19, 2024 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 51,115 | $48.1K | — | Dec 19, 2024 | Form 4 ↗ 1 day later · 51,115 shares | Form 144 ↗ |
| Dec 18, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 85,035 | $84.2K | — | Dec 18, 2024 | Form 4 ↗ 1 day later · 132,030 shares | Form 144 ↗ |
| Dec 17, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 46,995 | $47.3K | — | Dec 17, 2024 | Form 4 ↗ 2 days later · 132,030 shares | Form 144 ↗ |
| Nov 19, 2024 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 7,785 | $7,878 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 7,785 shares | Form 144 ↗ |
| Nov 19, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 6,407 | $6,483 | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 6,407 shares | Form 144 ↗ |
| Nov 19, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 16,278 | $16.5K | — | Nov 19, 2024 | Form 4 ↗ 1 day later · 16,278 shares | Form 144 ↗ |
| Aug 19, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 5,651 | $7,211 | — | Aug 19, 2024 | — | Form 144 ↗ |
| Aug 19, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 14,881 | $19.0K | — | Aug 19, 2024 | — | Form 144 ↗ |
| Aug 19, 2024 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 6,866 | $8,762 | — | Aug 19, 2024 | — | Form 144 ↗ |
| Jun 14, 2024 | Robert Chess Director | NKTR Nektar Therapeutics | 19,500 | $23.4K | 10b5-1 | Jun 14, 2024 | — | Form 144 ↗ |
| May 17, 2024 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 7,355 | $12.9K | — | May 17, 2024 | — | Form 144 ↗ |
| May 17, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 6,260 | $11.0K | — | May 17, 2024 | — | Form 144 ↗ |
| May 17, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 16,650 | $29.2K | — | May 17, 2024 | — | Form 144 ↗ |
| Feb 20, 2024 | Howard W. Robin Officer, Director | NKTR Nektar Therapeutics | 20,033 | $13.6K | — | Feb 20, 2024 | — | Form 144 ↗ |
| Feb 20, 2024 | Mark Andrew Wilson Officer | NKTR Nektar Therapeutics | 7,606 | $5,149 | — | Feb 20, 2024 | — | Form 144 ↗ |
| Feb 20, 2024 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 9,014 | $6,102 | — | Feb 20, 2024 | — | Form 144 ↗ |
| Dec 15, 2023 | Roy A. Whitfield Director | NKTR Nektar Therapeutics | 14,000 | $6,860 | 10b5-1 | Dec 15, 2023 | — | Form 144 ↗ |
| Nov 17, 2023 | Jonathan Zalevsky Officer | NKTR Nektar Therapeutics | 9,646 | $4,723 | — | Nov 17, 2023 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 7:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances